ENGOT EN20

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR/ PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Description: This placebo controlled, double-blind trial assesses the effectiveness of Selinexor as maintenance treatment in women with P53 wild type, advanced or recurrent endometrial cancer
Study Phase: Phase 3
Principal Investigator: Prof Karen Cadoo
Further information

MK2870-033

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Advanced/ Recurrent Endometrial Cancer (TroFuse-033)
Description: This a Phase 3 clinical trial testing if adding a new targeted drug, Sacituzumab Tirumotecan (Sac-TMT), to Pembrolizumab works better than Pembrolizumab alone. It is for patients with first-line advanced or recurrent, mismatch repair-proficient (pMMR) endometrial cancer.
Study Phase: Phase 3
Principal Investigator: Prof Karen Cadoo
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry